Each month the Lupus Forum Steering Committee selects the latest published original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
Literature Highlights - February 2023
long term economic burden, neurologic, psychiatric, international, multi-ethnic, SLE, criteria, classification, damage, lupus, prognosis, autoimmune diseases, biological therapy, glucocorticoids, systemic lupus erythematosus, health-related quality of life, interferon signature, SLEDAI, transcriptomic, patient-reported outcome, fatigue, disease activity, mediation analysis
Literature Highlights - January 2023
systematic review, targeted treatments, biologics, clinical trial, belimumab, anifrolumab, Bruton’s Tyrosine Kinase, BTK, inhibitor, evobrutinib, SLE, systemic lupus erythematosus, dose-ranging, pregnancy, obstetric comorbidities, , childhood-onset SLE (cSLE), treatment, safety, CD40 ligand, dapirolizumab pegol, exposure-response, population pharmacokinetics
Literature Highlights - December 2022
biologicals, b-lymphocytes, biomarkers, systemic lupus erythematosus, deucravacitinib, TYK2, Phase II, anifrolumab, Phase III, long-term, safety, IL-2, interleukin-2, Treg, SLE
Literature Highlights - July 2022
The July 2022 literature review is comprised of six papers reviewing the efficacy and safety of treatment methods in lupus.